Display options
Cite
Insel PS, Palmqvist S, Mackin RS, et al. Assessing risk for preclinical β-amyloid pathology with . Alzheimers Dement (Amst). 2016;4:76-84doi: 10.1016/j.dadm.2016.07.002.
Insel, P. S., Palmqvist, S., Mackin, R. S., Nosheny, R. L., Hansson, O., Weiner, M. W., & Mattsson, N. (2016). Assessing risk for preclinical β-amyloid pathology with . Alzheimer's & dementia (Amsterdam, Netherlands), 476-84. https://doi.org/10.1016/j.dadm.2016.07.002
Insel, Philip S, et al. "Assessing risk for preclinical β-amyloid pathology with ." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 4 (2016): 76-84. doi: https://doi.org/10.1016/j.dadm.2016.07.002
Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N. Assessing risk for preclinical β-amyloid pathology with . Alzheimers Dement (Amst). 2016 Aug 03;4:76-84. doi: 10.1016/j.dadm.2016.07.002. eCollection 2016. PMID: 27722193; PMCID: PMC5045949.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2016 Aug 03;4:76-84. doi: 10.1016/j.dadm.2016.07.002. eCollection 2016.

Assessing risk for preclinical β-amyloid pathology with .

Alzheimer's & dementia (Amsterdam, Netherlands)

Philip S Insel, Sebastian Palmqvist, R Scott Mackin, Rachel L Nosheny, Oskar Hansson, Michael W Weiner, Niklas Mattsson

Affiliations

  1. Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden; Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
  2. Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden.
  3. Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, CA, USA.
  4. Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA.
  5. Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
  6. Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.

PMID: 27722193 PMCID: PMC5045949 DOI: 10.1016/j.dadm.2016.07.002

Abstract

INTRODUCTION: Clinical trials in Alzheimer's disease are aimed at early stages of disease, including preclinical Alzheimer's disease. The high cost and time required to screen large numbers of participants for Aβ pathology impede the development of novel drugs. This study's objective was to evaluate the extent to which inexpensive and easily obtainable information can reduce the number of screen failures by increasing the proportion of Aβ+ participants identified for screening.

METHODS: We used random forest models to evaluate the positive predictive value of demographics,

RESULTS: Predicting Aβ positivity with demographic,

CONCLUSIONS: By incorporating this procedure, clinical trial screening costs of 7500 USD per participant may be reduced by nearly 7 million USD total.

Keywords: APOE; Amyloid; Clinical trials; Cognition; Preclinical Alzheimer's

References

  1. Clin Chem. 2005 Feb;51(2):336-45 - PubMed
  2. JAMA Neurol. 2016 Jan;73(1):85-92 - PubMed
  3. Ann Neurol. 2009 Apr;65(4):403-13 - PubMed
  4. Lancet Neurol. 2014 Oct;13(10 ):997-1005 - PubMed
  5. Neurology. 2012 Oct 9;79(15):1570-7 - PubMed
  6. J Alzheimers Dis. 2010;20 Suppl 2:S527-33 - PubMed
  7. Neuroimage Clin. 2013 Mar 05;2:356-65 - PubMed
  8. J Alzheimers Dis. 2016;51(4):1145-55 - PubMed
  9. Ann Clin Transl Neurol. 2015 May;2(5):534-47 - PubMed
  10. Neurology. 2016 May 17;86(20):1887-96 - PubMed
  11. Arch Gen Psychiatry. 1998 Sep;55(9):809-15 - PubMed
  12. Ann Neurol. 2010 Jan;67(1):122-31 - PubMed
  13. JAMA Neurol. 2015 May;72(5):511-9 - PubMed
  14. Neurology. 2013 Apr 2;80(14 ):1341-8 - PubMed
  15. Brain. 2015 Jul;138(Pt 7):2020-33 - PubMed
  16. JAMA. 2015 May 19;313(19):1924-38 - PubMed
  17. Neuropsychologia. 2011 Jul;49(9):2384-90 - PubMed
  18. Neurology. 2012 Oct 16;79(16):1636-44 - PubMed
  19. Ann Neurol. 1992 Sep;32(3):371-5 - PubMed
  20. Ann Neurol. 2012 Oct;72 (4):578-86 - PubMed
  21. Trends Pharmacol Sci. 2015 May;36(5):297-309 - PubMed
  22. Sci Transl Med. 2014 Mar 19;6(228):228fs13 - PubMed
  23. Neurobiol Aging. 2010 Aug;31(8):1275-83 - PubMed
  24. Am J Psychiatry. 1997 Feb;154(2):165-72 - PubMed
  25. Am J Psychiatry. 1984 Nov;141(11):1356-64 - PubMed
  26. JAMA Neurol. 2014 Jun;71(6):725-34 - PubMed

Publication Types

Grant support